iShares MSCI Australia UCITS ETF logo

iShares MSCI Australia UCITS ETF (IBC6)

Market Closed
10 Aug, 15:30
56. 55
-0.58
-1.0152%
- Market Cap
- Div Yield
15,997 Volume
57.13
Previous Close
Add Transaction
Day Range
56.43 56.71
Year Range
45.63 57.22
Want to track IBC6 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

IBC6 closed today lower at €56.55, a decrease of -1.0152% from yesterday's close, completing a monthly increase of 1.5443% or €0.86. Over the past 12 months, IBC6 stock gained 16.9718%.
IBC6 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on SIX (AUD).

IBC6 Chart

iShares MSCI Australia UCITS ETF (IBC6) FAQ

What is the stock price today?

The current price is €56.55.

On which exchange is it traded?

iShares MSCI Australia UCITS ETF is listed on XETRA.

What is its stock symbol?

The ticker symbol is IBC6.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has iShares MSCI Australia UCITS ETF ever had a stock split?

No, there has never been a stock split.

iShares MSCI Australia UCITS ETF Profile

XETRA Exchange
US Country

Overview

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions. Established in 2015 and based in San Diego, California, the company is committed to improving the care and protection for patients experiencing life-threatening allergic reactions, also known as anaphylaxis. ARS Pharmaceuticals aims to serve a broad audience, including healthcare professionals, patients, and caregivers, by providing advanced, patient-friendly solutions for emergency situations.

Products and Services

neffy: The flagship product under development by ARS Pharmaceuticals, Inc. is neffy, a needle-free, intranasal epinephrine nasal spray designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Unlike traditional epinephrine auto-injectors, neffy offers a non-invasive, low-dose alternative that could transform the way severe allergic reactions are treated. The innovative nasal spray form aims to make administration less intimidating and more accessible in critical moments, thereby potentially increasing the likelihood of timely and effective treatment.

Contact Information

Address: 11682 El Camino Real
Phone: 858 335 1300